Survey
SURVEY: Understanding the potential impact of Risdiplam on Spinraza in SMA
Ticker(s): RHHBY, BIIB, NVSHow many of your SMA patients have you prescribed Spinraza? [Number]
Have you prescribed Risdiplam to any of your SMA patients?
Of the patients you have prescribed Risdiplam how many were:
- Switches from Spinraza: [Number]
- SMA patients not on Spinraza: [Number]
- In combination with Spinraza [Number]
How many of your SMA patients currently on Spinraza do you anticipate switching to Risdiplam in:2021: [number]2022: [number]2023: [number]
How do you view the efficacy of Risdiplam compared to Spinraza in patients in your clinical practice?
- Risdiplam is significantly more efficacious compared to Spinraza.
- Risdiplam is more efficacious compared to Spinraza.
- Risdiplam is equally efficacious compared to Spinraza.
- Risdiplam is significantly less efficacious compared to Spinraza.
- Risdiplam is less efficacious compared to Spinraza.
Do you anticipate starting SMA patients not currently treated on Spinraza going forward? [yes/no]
With regards to prior question, why or why not?
. What % of your current SMA patients would fall in to these 4 treatment buckets: (should add to 100%)
- On Spinraza, not Risdiplam: [%?]
- On Risdiplam, not Spinraza: [%?]
- On both Spinraza and Risdiplam: [%?]
- Treated with only Zolgensma, no maintenance treatment with Spinraza or Risdiplam [%]
- Untreated: [%]
In 2023 what % of your patients would estimate fall in to these 4 treatment buckets:
- On Spinraza, not Risdiplam: [%?]
- On Risdiplam, not Spinraza: [%?]
- On both Spinraza and Risdiplam: [%?]
- Treated with only Zolgensma, no maintenance treatment with Spinraza or Risdiplam [%]
- Untreated: [%]
How many treatment naïve patients do you have? [Number]
How many of your treatment naïve patients do you plan to start on:
- Spinraza [Number]
- Risdiplam [Number]
- Zolgensma [Number]
- No therapy [Number]
Are You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
